Verition Fund Management
CYTK icon

Verition Fund Management’s Cytokinetics CYTK Stock Holding History

Verition Fund Management’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$4.68M Buy
+54,889
New +$3.94M 0.02% 688
2025
Q2 		– Sell
-34,037
Closed -$1.37M – 3674
2025
Q1 		$1.37M Buy
34,037
+13,755
+68% +$632K 0.01% 1860
2024
Q4 		$954K Sell
20,282
-17,581
-46% -$913K ﹤0.01% 2083
2024
Q3 		$2M Buy
37,863
+27,098
+252% +$1.51M 0.01% 1418
2024
Q2 		$583K Sell
10,765
-151,554
-93% -$9.15M ﹤0.01% 1974
2024
Q1 		$11.4M Buy
+162,319
New +$12.6M 0.08% 290
2022
Q3 		– Sell
-6,970
Closed -$274K – 3076
2022
Q2 		$274K Buy
+6,970
New +$281K 0.01% 1766
2015
Q1 		– Sell
-15,988
Closed -$128K – 406
2014
Q4 		$128K Buy
+15,988
New +$68.6K 0.03% 274

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Verition Fund Management's CYTK Position: Q2 2026 in Review

Verition Fund Management opened a new position in Cytokinetics (CYTK) in Q2 2026: 54,889 shares worth $4.68M. The stake represents 0.02% of the portfolio and ranks #688 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in CYTK as recently as Q1 2025.

Verition Fund Management first reported a position in CYTK in Q4 2014 and has held it in 8 quarters since. The position peaked at $11.4M in Q1 2024. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Verition Fund Management held 54,889 shares of Cytokinetics worth $4.68M as of Q2 2026.
  • Cytokinetics was a new Verition Fund Management position in Q2 2026.
  • Cytokinetics made up 0.02% of Verition Fund Management's portfolio in Q2 2026, its #688 holding.
  • Verition Fund Management first reported a position in Cytokinetics in Q4 2014 and has held it in 8 quarters since.
  • Verition Fund Management's Cytokinetics position peaked at $11.4M in Q1 2024.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.